Information intended for healthcare professionals. This checklist was developed from content provided by Bayer plc and the format was developed by Guidelines. Please see the bottom of the page for full disclaimer.

View Xarelto (rivaroxaban) prescribing information and adverse event reporting information

Download the checklist

If the PDF does not load within 5 seconds, please refresh the page.

 

For additional information consult:

*Rivaroxaban is indicated for treatment of DVT and  PE, and prevention of recurrent DVT and PE in adults. 

DVT=deep vein thrombosis; HCP=healthcare professional; PE=pulmonary embolism; SmPC=summary of product characteristics

This checklist was developed from content provided by Bayer plc and the format was developed by Guidelines. Bayer plc carried out approval to ensure compliance with regulations. No part of this publication may be reproduced in any form without the permission of the publisher.

PP-XAR-GB-1416

Date of preparation: June 2020